Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alexander Nowak maintains a Buy rating on Bioventus (NASDAQ:BVS) and raises the price target from $12 to $17.
September 27, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Craig-Hallum analyst Alexander Nowak has reaffirmed a Buy rating for Bioventus and increased the price target from $12 to $17, indicating a positive outlook for the stock.
The reaffirmation of a Buy rating and an increase in the price target from $12 to $17 by Craig-Hallum suggests a positive sentiment towards Bioventus. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100